Q3 2025 Financial Performance - Revenue reached $337 million, a 26% year-over-year increase[7] - Adjusted EBITDA grew by 46% year-over-year to $78 million, with a margin of 232%, a 320 bps improvement[7] - Cash from Operations increased by 68% year-over-year to $58 million[7] - Free cash flow grew by 83%[8] Customer Growth and ARPU - Total scaled customers increased by 20% year-over-year to 572, while super-scaled customers grew by 25% to 180[10] - Scaled customer ARPU increased to $579,000, a 4% year-over-year growth[10] - Super-scaled customer ARPU remained at $16 million[10] Guidance and Future Targets - The company is raising FY25 revenue guidance to $1275 million and adjusted EBITDA guidance to $2737 million[8,38] - Initial FY26 revenue guidance is set at $1540 million, representing a 21% year-over-year growth[8,46] - The company targets $21 billion+ in revenue, $525 million+ in adjusted EBITDA, and $340 million+ in free cash flow by 2028[34] Data and Technology - US Individuals Providing Permission to Online Tracking by Agreeing to Publisher Terms of Service is 245M[108] - US Individuals Providing Permission to Email via Opt-in Action is 110M[108]

Grocery Outlet Business Overview November 2025 Data in this presentation is generally as the fiscal year ended December 28, 2024, unless otherwise noted Disclaimer Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of historical fact, including statements regarding the Company's future operating results and financial position, the Compa ...

Financial Performance - Total revenue increased to $132 million in Q3 2025, a 14% year-over-year growth compared to $116 million in Q3 2024[10] - Testing revenue reached $128 million in Q3 2025, a 17% year-over-year increase from $110 million in Q3 2024[10] - Adjusted EBITDA margin was 30.1% in Q3 2025, compared to 23.6% in Q3 2024[34] - The company raised full-year revenue guidance to $506 - $510 million and adjusted EBITDA margin expectations to over 25%[36] - Cash and short-term investments increased to $366 million at the end of Q3 2025, compared to $274 million in Q3 2024[34] Testing Volume and Growth - Testing volume increased to 43,700 in Q3 2025, a 19% year-over-year growth compared to 36,800 in Q3 2024[10] - Decipher test quarterly volume continued to grow, with a 26% increase[16] - Afirma test quarterly volume also experienced growth, with a 13% increase[21] Strategic Initiatives and Product Development - The company is transitioning to v2 Veracyte transcriptome to improve operational efficiency[14] - Commercial launch of TrueMRD for muscle invasive bladder cancer (MIBC) is on track for the first half of 2026[25] - Prosigna LDT launch is on track for mid-2026 in the CLIA lab[26]

Business Highlights - OmniAb has 104 active partners as of September 30, 2025 [13] - The company has 399 active programs as of September 30, 2025, a net addition of 36 programs year-to-date [16, 18] - There are 32 active clinical programs and approved products as of September 30, 2025 [26] - OmniAb is launching OmniUltra in December, a new technology for antibody and peptide therapeutics discovery [11, 41] Financial Performance - Q3 2025 total revenue was $22 million, compared to $42 million in Q3 2024 [65] - License and milestone revenue decreased to $06 million in Q3 2025 from $14 million in Q3 2024 [65] - Service revenue decreased to $12 million in Q3 2025 from $25 million in Q3 2024 [65] - Royalty revenue increased to $04 million in Q3 2025 from $03 million in Q3 2024 [65] - Research and Development expenses decreased to $104 million in Q3 2025 from $133 million in Q3 2024 [65] - Net loss was ($165) million in Q3 2025, compared to ($164) million in Q3 2024 [65] Financial Guidance - The company expects 2025 revenue to be in the range of $18 to $22 million [67] - The company expects 2025 operating expense to be in the range of $82 to $86 million [67]

Financial Performance - Revenue for Q3 2025 was $463 million, a 24% increase year-over-year (YoY)[4, 11] - Non-GAAP EPS for Q3 2025 was $1.74, up 78% YoY[4, 11] - Non-GAAP gross margin for Q3 2025 was 39.1%, a 100 basis points increase quarter-over-quarter (QoQ)[4, 11] - Total cash reached $759 million[4] - Operating cash flow was $79 million[4] Market Segment Performance - Data Center Computing revenue increased 21% QoQ and 113% YoY, reaching $172 million[15, 14, 19] - Semiconductor Equipment revenue decreased 6% QoQ but remained relatively flat YoY at $197 million[12, 14, 19] - Industrial & Medical revenue increased 4% QoQ but decreased 7% YoY, totaling $71 million[16, 14, 19] - Telecom & Networking revenue increased 10% QoQ and 24% YoY, reaching $24 million[13, 14, 19] Future Outlook - The company raised its 2025 growth forecast to 20% YoY[9] - Q4 2025 revenue is guided at $470 million, plus or minus $20 million[24] - Q4 2025 non-GAAP EPS is guided at $1.75, plus or minus $0.25[24]

1 © 2025 Arteris, Inc. November 4, 2025 Disclaimer This presentation and the accompanying oral presentation have been prepared by Arteris, Inc. ("Arteris" or "the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Arteris or any officer, director, employee, agent or advisor of Arteris. This presentation does not purport to be all-inclusive or to contain ...

Financial Performance & Outlook - The company narrows its net sales guidance for 2025 to a range of $540 million to $550 million, reflecting a 7% year-over-year growth at the midpoint[26] - Adjusted EBITDA guidance is narrowed to $92 million to $98 million, indicating a 19% year-over-year growth at the midpoint[26] - Capital expenditures guidance is revised to $22 million to $24 million, reflecting project efficiencies and timing shifts[26] - Net sales for the three fiscal quarters ended September 27, 2025, reached $445962 thousand, with an Adjusted EBITDA of $89354 thousand and an Adjusted EBITDA margin of 200%[41] - Net debt leverage ratio as of September 27, 2025, is 23, with a net debt of $210555 thousand and LTM Adjusted EBITDA of $92976 thousand[44] Market Position & Growth Strategy - The company holds the number one share in every subcategory in which it competes[9] - The company has approximately 50% share of the fiberglass category in North America[10] - Fiberglass constitutes 23% of total pool installs, marking a 600 bps increase[11] - Replacement sales account for 51% of liners and covers[13] - The company is expanding its share in the Sand States through new dealer sign-ups, presence in Master Planned Communities, and aligning products with demand[18][19][20] Market Dynamics - The company forecasts new U S pool starts in 2025 to be flat to slightly down compared to 2024 levels[25][29]

Q3 2025 Financial Results N O V E M B E R 4 , 2 0 2 5 Safe Harbor Statement These slides and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation, including statements regarding the future financial position of CareDx®, Inc. (together with its subsidiaries, "Care ...

This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, In ...

Third Quarter 2025 Earnings November 4, 2025 1 Safe Harbor Statement Executive Summary | Continuing Operations(1) | Continuing Operations(1) | Executive Summary | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Non-GAAP results including new tariffs: | Non-GAAP results including new tariffs: | Revenue(2) | Revenue(2) | million grew 8% on a constant currency(3) | million grew 8% on a constant currency(3) | • | • | of $371 | of $3 ...